Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma

Jonathan Corren, Mario Castro, Pascal Chanez, Leonardo Fabbri, Vijay N. Joish, Nikhil Amin, Neil M.H. Graham, Vera Mastey, Adeline Abbé, Christine Taniou, Puneet Mahajan, Ariel Teper, Gianluca Pirozzi, Laurent Eckert

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


Background: In a pivotal, phase 2b study (NCT01854047) in patients with uncontrolled persistent asthma, despite using medium-to-high-dose inhaled corticosteroids plus long-acting β2 agonists, dupilumab improved lung function, reduced severe exacerbations, and showed an acceptable safety profile. Objective: To assess the impact of dupilumab on asthma control, symptoms, quality of life (QoL), and productivity. Methods: Data are shown for the intention-to-treat population receiving dupilumab 200/300 mg every 2 weeks (doses being assessed in phase 3; NCT02414854), or placebo. Predefined analyses of total scores were conducted at week 24 for the 5-item Asthma Control Questionnaire (ACQ-5), patient-reported morning/evening (AM/PM) asthma symptoms, Asthma Quality of Life Questionnaire (AQLQ), and asthma-related productivity loss. Responder rate analyses for these measures, subgroup analyses by baseline characteristics, and asthma-related productivity loss analyses were conducted post hoc. Results: Data from 465 patients were analyzed (158 placebo; 307 dupilumab). Both dupilumab doses significantly improved scores through week 24 (all outcomes, overall population). The proportion of patients meeting or exceeding the minimal clinically important difference for the overall population were significantly greater vs placebo (P < .05) for ACQ-5 (range, 72.6%-76.7% vs 61.4%), for AM/PM asthma symptoms score (48.7%-54.1% vs 34.2% and 52.7%-53.5% vs 34.2%, respectively) and for AQLQ (64.0%-65.0% vs 51.3%). The effect of dupilumab was consistent across most subgroups. Productivity loss was significantly higher in placebo- vs dupilumab-treated patients (P < .0001). Conclusion: Dupilumab produced significant, clinically meaningful improvements in asthma control, symptoms, QoL, and productivity. Registration: ClinicalTrials.gov Identifier: NCT01854047.

Original languageEnglish
Pages (from-to)41-49.e2
JournalAnnals of Allergy, Asthma and Immunology
Issue number1
StatePublished - Jan 2019


Dive into the research topics of 'Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma'. Together they form a unique fingerprint.

Cite this